A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

The least-squares mean change in A1c was significant compared with placebo in all three LY dosing groups: LY0.5/1 = -1.38%, LY1/1 = -1.32%, LY1/2 = -1.59%. The reduction seen with LY1/2 was also ...

interactive diabetes self-management education programs such as the Conversation Map tools may be an effective model for the reduction of patient A1c levels.

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

Published and preliminary data have shown once-weekly exenatide to result in greater A1c reduction than exenatide twice daily; and as a second- or third-line therapy, it is more efficacious in ...